Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

Matcha mania is sweeping the world. The bright green Japanese tea can be found in everything from Starbucks’ lattes in the UK ...

Takeda is making waves in data and artificial intelligence (AI) with Informatica and AWS: 90% of data moved to the cloud, 40% higher productivity and millions saved in IT overhead. Discover how ...

KalVista Pharmaceuticals faces a shrinking HAE market, tough competition, and launch uncertainty despite FDA approval. Read ...

Takeda Pharmaceutical (TAK) said Monday it has received 510 (k) clearance for its HyHub and HyHub Duo PREMIUM Upgrade to read ...

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 30 Jun 2025 OSAKA, Japan & CAMBRIDGE, Mass.

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

It may be her first start as a professional, but Lottie Woad is showing no signs of slowing down from her recent form.

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.